https://www.avient.com/sites/default/files/2025-02/News Release - AVNT-2024.12.31-News Release 2.12.25 2PM_0.pdf
The company noted that full year 2024 GAAP EPS includes special items of $0.17 (see attachment 3) and $0.65 of intangible amortization expense (see attachment 1).
Organic sales grew in all geographic regions with the U.S. and Canada growing at 6%, EMEA at 1%, Asia at 7% and Latin America at 14%.” 2 Commenting on full year 2024 results, Dr.
A recording of the webcast and the slide presentation will be available at avient.com/investors/events-presentations immediately following the conference call and will be accessible for one year. https://www.avient.com/investors https://edge.media-server.com/mmc/p/rgfk7qte/ https://www.avient.com/investors https://register.vevent.com/register/BIf718eaf1419a4d83a527f0aba7b74d90 https://www.avient.com/investors/events-presentations 4 Non-GAAP Financial Measures The Company uses both GAAP (generally accepted accounting principles) and non-GAAP financial measures.
https://www.avient.com/sites/default/files/2020-10/auto-injector-application-study.pdf
Autoinjector Pen - Avient Application Study.mm (1) AUTO-INJECTOR APPLICATION STUDY M A T E R I A L T E C H N O L O G I E S + S E R V I C E S F O R N E X T G E N E R A T I O N D E S I G N S Avient Corporation 1 Avient Corporation 2 Innovating Design Medical innovations and plastics have gone hand-in-hand to make healthcare safer, cleaner, and more accessible for all.
We can help tackle your toughest challenges with our • In-depth industry knowledge • Expansive material solutions • Far-reaching technical capabilities and services Avient Corporation 4 1 Injection window Integrated rigid needle shield 2 Cap 3 1.
Requirements: USP Class VI skin contact colorant for drug differentiation Solution: OnColor™ HC, MEVOPUR® 4 Button 5 Batch or SKU identifier Safety and trigger cap 6 DRUG CONCENTRATION 1 DRUG CONCENTRATION 2 DRUG CONCENTRATION 3 Patient Handling Age or certain disease states can severely limit patient dexterity making the self-administration of medication difficult and frustrating.
https://www.avient.com/sites/default/files/2025-02/31307-Certificate-17JUL2024.pdf
Page 1 of 4 https://abs.ez2xs.com https://abs.ez2xs.com A B S Q u al ity E va lu at io n s C er tif ic at io n E ISO 9001:2015 Certificate Of Conformance ANNEX Certificate No.: 31307 Avient Corporation At the below facilities FACILITY NAME FACILITY ACTIVITY ADDRESS Avient - Birmingham Manufacturing The Manufacture of Pultruded and Filament wound components Pultrusion and CRTM 3943, Valley East Industrial Drive, Buildings 1,2,3,4 Birmingham - AL 35217 United States Avient - Birmingham Manufacturing The Manufacture of Pultruded and Filament wound components Pultrusion and Filament Wound Tubing 3968, Valley East Industrial Drive, Building 5 Birmingham - AL 35217 United States Avient - Birmingham Manufacturing The Manufacture of Pultruded and Filament wound components Pultrusion 3950, Valley East Industrial Drive, Building 6 Birmingham - AL 3517 United States Avient Corporation Management of QMS.
Page 3 of 4 https://abs.ez2xs.com https://abs.ez2xs.com A B S Q u al ity E va lu at io n s C er tif ic at io n E Avient Corporation - Mountain Top, PA Manufacturing, Shipping and Receiving , 855 Oak Hill Road Mountain Top - PA 18707 United States Avient Corporation - Oricain (Pamplona), Spain Design and Manufacture of Color and Additive Concentrates and Specialty Compounds Pol.
Page 4 of 4 https://abs.ez2xs.com https://abs.ez2xs.com
https://www.avient.com/sites/default/files/resources/PolyOne%2520Standard%2520Quality%2520Response_2016_6_9.pdf
Avon Lake, OH 44012 P: +1 (440) 930-3000 I: +1 (866) 737-2066 F: +1 (440) 930-3064 Dear Valued Customer: Thank you for your inquiry regarding the quality system at PolyOne.
Yes. 5.2 Supplier Management 1.
1 to 21 days based on the specific product and/or process. 3.
https://www.avient.com/sites/default/files/2025-05/Avient Announces First Quarter 2025 Results_0.pdf
The company noted that first quarter 2025 GAAP EPS includes special items of $0.82 primarily related to an impairment associated with ceasing the development of S/4HANA, a cloud-based ERP system (see attachment 3), and $0.16 of intangible amortization expense (see attachment 1).
A recording of the webcast and the slide presentation will be available at avient.com/investors/events-presentations immediately following the conference call and will be accessible for one year. https://www.avient.com/investors https://edge.media-server.com/mmc/p/tay7mbuw/ https://www.avient.com/investors https://register-conf.media-server.com/register/BI648915d05d0c44c4bdef681472840ace https://www.avient.com/investors/events-presentations 3 Non-GAAP Financial Measures The Company uses both GAAP (generally accepted accounting principles) and non-GAAP financial measures.
Rose Vice President, Corporate Communications Avient Corporation +1 440-930-3162 kyle.rose@avient.com 6 Attachment 1 Avient Corporation Reconciliation of Adjusted Net Income and Earnings Per Share (Unaudited) (In millions, except per share data) Senior management uses comparisons of adjusted net income attributable to Avient common shareholders and diluted adjusted earnings per share (EPS) attributable to Avient common shareholders, excluding special items, to assess performance and facilitate comparability of results.
https://www.avient.com/sites/default/files/resources/Ramos%2520IATF%252016949-2016%2520exp%25207-10-2021_0.pdf
For and on behalf of BSI: Carlos Pitanga, Chief Operating Officer Assurance – Americas Certification Date: 2018-07-11 Latest Issue: 2018-07-11 Expiry Date: 2021-07-10 BSI Certificate Number: 85585 IATF Number: 0315491 Page: 1 of 2 This certificate remains the property of BSI and shall be returned immediately upon request.
Americas Headquarters: BSI Group America Inc., 12950 Worldgate Drive, Suite 800, Herndon, VA 20170-6007 USA A Member of the BSI Group of Companies. https://pgplus.bsigroup.com/CertificateValidation/CertificateValidator.aspx?
Americas Headquarters: BSI Group America Inc., 12950 Worldgate Drive, Suite 800, Herndon, VA 20170-6007 USA A Member of the BSI Group of Companies. https://pgplus.bsigroup.com/CertificateValidation/CertificateValidator.aspx?
https://www.avient.com/sites/default/files/resources/PolyOne%2520IR%2520Presentation%2520-%2520Seaport%2520Global%2520Transports%2520%2526%2520Industrials%2520Conference.pdf
Addressable market exceeds $40 billion Strong performance demonstrates that our strategy and execution are working Megatrends and emerging opportunities align with strengths Innovation and services provide differentiation, incremental pricing power and competitive advantage Strategic balance between reinvestment for growth and returning cash to shareholders Strong and proven management team driving growth and performance 18 POLYONE CORPORATION Segment Highlights POLYONE CORPORATION 19 2016 Revenue: $0.8 Billion At a Glance: Color, Additives & Inks Key Applications 2016 Revenue by Industry Expanding Profits 1.7% 4.6% 5.1% 5.5% 7.2% 8.1% 9.7% 12.2% 14.7% 16.7% 16.0% 20%+ 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2020 Operating Income % of Sales Platinum Vision United States 45% Europe 33% Asia 15% Latin America 5% Canada 2% Packaging 30% Industrial 15% W & C 10% B & C 10% Textiles 9% Transportation 9% Consumer 7% Healthcare 6% Appliance 2% E & E 2% POLYONE CORPORATION 20 2016 Revenue: $0.6 Billion At a Glance: Specialty Engineered Materials 2016 Revenue by Industry Expanding Profits 1.1% 1.3% 3.4% 5.1% 9.6% 8.0% 8.6% 9.3% 12.1% 14.7% 14.3% 20%+ 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2020 Operating Income % of Sales Platinum Vision Consumer 19% Transportation 19% E & E 15% W & C 15% Healthcare 11% Industrial 8% Packaging 7% Appliance 3% B & C 3% United States 51% Europe 27% Asia 20% Canada 2% Key Applications POLYONE CORPORATION 21 2016 Revenue: $0.4 Billion At a Glance: Designed Structures & Solutions 2016 Revenue by Industry Expanding Profits 1.4% 5.6% 7.3% 3.0% 8-10% -0.9% 2012 2013 2014 2015 2016 2020 Operating Income % of Sales Platinum Vision Transportation 27% Industrial 21% Packaging 21% B & C 11% Healthcare 8% Consumer 8% Appliance 3% E & E 1% Key Applications United States 95% Canada 5% http://www.google.com/url?
sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0CAcQjRw&url=http://www.mullerquaker.com/products/greek100/greek100-peach-and-passion-fruit&ei=-acYVZq7EIqwyASDjYL4CA&bvm=bv.89381419,d.cWc&psig=AFQjCNGNCQY1_dCN2RPLzxtap_Pu0omTXQ&ust=1427765484498432 POLYONE CORPORATION 22 2016 Revenue: $0.7 Billion At a Glance: Performance Products & Solutions 2016 Revenue by Industry Expanding Profits 5.5% 6.9% 3.8% 3.6% 5.5% 4.3% 6.3% 7.2% 7.7% 8.3% 12-14% 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2020 Operating Income % of Sales Platinum Vision 11.1% B & C 30% Transportation 18% W & C 16% Industrial 16% Appliance 6% Consumer 5% Packaging 5% E & E 3% Healthcare 1% United States 78% Canada 16% Latin America 4% Asia 2% Key Applications POLYONE CORPORATION 23 2016 Revenue: $1.1 Billion At a Glance: Distribution Key Suppliers ROIC Expanding Profits 2.6% 3.0% 3.5% 4.0% 4.6% 5.6% 6.4% 5.9% 6.1% 6.6% 6.5-7.5% 6.4% 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2020 Operating Income % of Sales Platinum Vision 15% 51% 2006 2016 Transportation 24% Healthcare 22% Industrial 18% Consumer 15% Appliance 6% E & E 5% B & C 4% Packaging 4% W & C 2% http://www.polyone.com/Pages/VariationRoot.aspx 24 POLYONE CORPORATION Application Examples POLYONE CORPORATION 25 Luxury Packaging with Gravitech Density Modified Polymers Impart weight, sound and metallic finish to caps and closures for cosmetics and spirits applications Elevate quality and prestige perceptions among high-end consumers Eliminate time and cost associated with secondary operations and assembly POLYONE CORPORATION 26 Eliminate costs by increasing pigment density Enhance color performance without altering form and formulation Increase design capabilities by reducing weight and layer thickness Optimize Color Usage with OnColor Super Concentrates POLYONE CORPORATION 27 Inhibit microbial growth on polymer surface Enhance value or products and devices Highly versatile concentrate with the ability to be incorporated into a wide variety of products Combat Bacteria Formation with WithStand Antimicrobial Technology POLYONE CORPORATION 28 Medical Device Housings with Chemically Resistant Engineered Polymers Durable, long-lasting products stand up to the most aggressive disinfectants Minimize environmental stress cracking and discoloration One of the broadest medically approved polymer and colorant portfolios POLYONE CORPORATION 29 Color & Design Services Greater control of color development and supply chain Work across entire design process from concept to commercialization Inspire creativity in the use of polymer materials, colors and effects Innovative brand differentiation Faster development timelines POLYONE CORPORATION 30 Outdoor Applications Leading provider of high performance specialty materials for the recreational and sports & leisure industry Well positioned across all segments to address market needs Metal to Polymer Conversion Lightweighting Thermal Management Impact Performance Source: Outdoor Industry Association POLYONE CORPORATION 31 Fiber Colorants Solutions for clothing, apparel, footwear, automotive & sporting goods ColorMatrix Fiber Colorant Solutions Proprietary advanced liquid color formulations and equipment enable greater efficiency and productivity Eliminates aqueous dyeing and its associated wastewater treatment Solid Color Concentrates Extrusion-spun fibers colored via solid masterbatch POLYONE CORPORATION 32 High-Barrier Packaging Containers Capability to extrude up to 13 layers Strong oxygen and moisture vapor transmission protection Can be made symmetrical or asymmetrical to meet customized needs of broad variety of applications Barrier protection and superior sensory properties 1 Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Senior management uses comparisons of adjusted net income attributable to PolyOne common shareholders, adjusted earnings per share (EPS) attributable to PolyOne common shareholders and operating income before special items to assess performance and allocate resources because senior management believes that these measures are useful in understanding current profitability levels and that current levels may serve as a base for future performance.
Adjusted EPS attributable to PolyOne common shareholders is calculated as follows: 2009* 2010 2011 2012 2013 2014 2015 2016 Net income attributable to PolyOne common shareholders $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 165.2 Joint venture equity earnings, after tax (19.0) (14.7) (3.7) — — — — — Special items, before tax(1) (48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 35.5 Special items, tax adjustments(1) (27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (20.7) Adjusted net income attributable to PolyOne common shareholders $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 180.0 Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.13 Adjusted operating income is calculated as follows: 2006* 2016 Operating income $ 233.6 $ 281.9 Special items (1) (39.1) 35.3 Joint venture equity earnings (107.0) 0.0 Adjusted operating income $ 87.5 $ 317.2 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation. (1) Special items include charges related to specific strategic initiatives or financial restructuring such as: consolidation of operations; debt extinguishment costs; costs incurred directly in relation to acquisitions or divestitures; employee separation costs resulting from personnel reduction programs, plant realignment costs, executive separation agreements; asset impairments; mark-to-market adjustments associated with actuarial gains and losses on pension and other post-retirement benefit plans; environmental remediation costs, fines, penalties and related insurance recoveries related to facilities no longer owned or closed in prior years; gains and losses on the divestiture of operating businesses, joint ventures and equity investments; gains and losses on facility or property sales or disposals; results of litigation, fines or penalties, where such litigation (or action relating to the fines or penalties) arose prior to the commencement of the performance period; one-time, non-recurring items; the effect of changes in accounting principles or other such laws or provisions affecting reported results and tax adjustments.
https://www.avient.com/sites/default/files/2022-12/Cesa Anti-fog Plus Product Bulletin_CN.pdf
CESA Nofog Plus Product Bulletin_CN12.15-1
https://www.avient.com/sites/default/files/2020-09/sustainabilityreport2018.pdf
Tossiat, France 1.
Carson, California 1.
Tossiat, France 1.
https://www.avient.com/sites/default/files/2024-10/Avient_CodeConduct_2024_HIN2.pdf
इन दो सरल नि यमो ं का पालन कर े:ं 1.
avient.ethicspoint.com 1-877-228-5410 (USA).
वि षय-सचू ी परि चय हमार ी आचार सहंि ता सभ ी का समम्ान काम पर ईमानदार ी हमार े वय्ापार म े ं ईमानदार ी कॉरप्ोर टे सामाजि क ससंाधन और सपंरक् ससंाधन और सपंरक् जानकार ीजानकार ी आचार सहंि ता | 30 http://avient.ethicspoint.com http://avient.ethicspoint.com http://avient.ethicspoint.com उतत्र ी अम रेि काउतत्र ी अम रेि का व शैव्ि क मखुय्ालय एवन ल के, सयंकुत् राजय् अम रेि का 33587 वॉकर रोड एवन ल के, OH, सयंकुत् राजय् अम रेि का 44012 टोल फर् ी: +1 866 765 9663 फोन: +1 440 930 1000 फ कैस्: +1 440 930 3064 एशि या पर्शातंएशि या पर्शातं पर्कष् तेर् ीय मखुय्ालय शघंाई, च ीन 2F, बल्ॉक C 200 जि नस् ू रोड प डुोगं, 201206 शघंाई, च ीन दरूभाष: +86 (0) 21 6028 4888 फ कैस्: +86 (0) 21 6028 4999 दकष्ि ण अम रेि का दकष्ि ण अम रेि का पर्कष् तेर् ीय मखुय्ालय साओ पॉलो, बर्ाज़ ील Av.